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Prospects for the search of antiviral agents among 4-thiazolidinone derivatives, as well as the optimal directions 
of the main core structure optimization – namely C5 and N3, have been described. As the result of the screening 
performed (within the Antimicrobial Acquisition and Coordinating Facility programme), the values of the antiviral 
activity of the target 5-substituted-4-thiazolidinones with the carboxylic group (or its derivatives) in the N3 resi-
due in relation to a wide range of the viral panels have been determined. The active compounds, which can be 
regarded as promising structures in the anti-flu agent design, have been identified, as well as 3-{5-[2-chloro-3-(4-
nitrophenyl)-allylidene]-4-oxo-2-thioxothiazolidine-3-yl}-propionic (1) and –succinic acids (3) have been identified 
as hit-compounds with a marked anti-VZV activity (SI values – 27 and 38, respectively).
СКРИНІНГ ПРОТИВІРУСНОЇ АКТИВНОСТІ В РЯДУ С5 ТА N3 ЗАМІЩЕНИХ ПОХІДНИХ 4-ТІАЗОЛІДИНОНІВ
Д.В.Камінський
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Показано перспективність пошуку противірусних агентів серед похідних 4-тіазолідинонів, зазначені 
оптимальні напрямки оптимізації структури базового гетероциклу – положення С5 та N3. У результа-
ті проведеного скринінгу (в рамках міжнародної програми Antimicrobial Acquisition & Coordinating Facility) 
встановлено значення противірусної активності досліджуваних 5-заміщених-4-тіазолідинонів, що міс-
тять карбоксильну групу (або її похідні) в заміснику положення N3, відносно широкого спектра вірусів. 
Виділено ряд активних сполук, що можуть розглядатися як перспективні структури при дизайні аген-
тів, що діють на віруси грипу, а також ідентифіковано 3-{5-[2-хлор-3-(4-нітрофеніл)-аліліден]-4-оксо-2-
тіоксотіазолідин-3-іл}-пропанову кислоту (1) та -сукцинатну кислоту (3) як сполуки-хіти з виразною 
активністю щодо вірусу Варіцелла-Зостер (значення індексу селективності 27 та 38 відповідно).
СКРИНИНГ ПРОТИВОВИРУСНОЙ АКТИВНОСТИ В РЯДУ С5 И N3 ЗАМЕЩЕННЫХ ПРОИЗВОДНЫХ 
4-ТИАЗОЛИДИНОНОВ
Д.В.Каминский 
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Показана перспективность поиска противовирусных агентов среди производных 4-тиазолидинонов, 
отмечены оптимальные направления оптимизации структуры базового гетероцикла – положения 
С5 и N3. В результате проведенного скрининга (в рамках международной программы Antimicrobial 
Acquisition & Coordinating Facility) установлены значения противовирусной активности исследуемых 
5-замещенных-4-тиазолидинонов, которые содержат карбоксильную группу (или ее производные) в заме-
стителе положения N3 относительно широкого спектра вирусов. Выделено ряд активных соединений, 
которые могут рассматриваться как перспективные структуры при дизайне агентов, воздейству-
ющих на вирусы гриппа, а также идентифицировано 3-{5-[2-хлор-3-(4-нитрофенил)-алилиден]-4-оксо-
2-тиоксотиазолидин-3-ил}-пропановую кислоту (1) и -сукцинатную кислоту (3) как соединения-хиты с 
выразительной активностью относительно вируса Варицелла-Зостер (значения индекса селектив-
ности 27 и 38 соответственно).The search for new biologically active compounds based on the 4-thiazolidinone core [1-3] within dif-ferent approaches and strategies [4] is successfully 
implemented over last decades. This is reflected in a large number of patents for biologically active com-pounds and introduction of 4-thiazolidinone-based 
drugs (such as glitazones – PPARsγ-agonist; Epalre- stat, etc.) to the market. Thus, 4-thiazolidinones are considered as examples of privileged heterocycles in modern medical/pharmaceutical chemistry [5]. The “classical” directions in the area of development of drug-like small molecules among 4-thiazolidinones are the search of new antimicrobial, anticancer, anti-
diabetic, anti-inflammatory and antiviral agents.
Following the diversity of 4-thiazolidinones; the possibility of bioisosteric replacement, and chemi-
cal modification of the basic scaffolds a large num-ber of 4-thiazolidinone sub-types (e.g., derivatives of 2,4-thiazolidinedione, rhodanine, 2-amino(imino)- 4-thiazolidinone, 5-ylidene-4-thiazolidinones, etc.) are described. Among the subtypes mentioned 5-ylidene- 4-thiazolidinones and 4-thiazolidinone-3-carboxylic acids are the most studied and promising 4-thiazoli-dinones in the context of creating new drug-like mo- lecules [2, 3, 6]. These sub-types represent the main 
important directions of the chemical modification of the 4-thiazolidinone core, namely positions C5 and N3. It have been found that the presence of the ylidene 
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ISSN 2308-8303moiety in position C5 is desirable and often crucial for the biological effect of 4-thiazolidinones and its value [2, 7]. On the other hand, introduction of sub-stituents (mainly those containing a carboxyl group) in position N3 is regarded as the chemical route to 
the design of new compounds with a significant bio- logical activity, but also considered as one of the ap- proaches to decreasing toxicity of new compounds [8]. It should be also noted that 5-ylidene-4-thiazolidi-none-3-carboxylic acids are among the preferred hit-compounds when using various in silico approaches 
with the subsequent experimental confirmation of 
the high affinity level to numerous biological targets 
[9]. Such findings are often criticized because of ref-fering 4-thiazolidiones to the so-called “frequent hit- ters” or “pan assay interference compounds (PAINS)” (“frequent hits” are compounds assigned as high-af- 
finity ligands to the set of biotargets and tend to have 
a low specificity) [5, 10, 11]. Although, the debate of the importance of such approach remains open.The search for the antiviral agents among 4-thiazo- lidinone derivatives are mainly presented in two di- rections: the search for new anti-HIV agents and com- pounds for treating viral hepatitis. The target com-pounds, namely compounds bearing the C5-ylidene fragment and the carboxyl group containing a sub-stituent in position N3, are low molecular weight in- hibitors of a number of biological targets – HCV NS3 protease (hepatitis C virus protease NS3) and HCV NS3-4A protease (regarded as an analogue of HIV pro- tease) [12]; NS5B polymerase [13, 14] and NS3(5) helicase; HIV RT (reverse transcriptase of HIV) [15]; RNA helicase DDX3 [16] HIV-1 integrase [17], etc. However, the screening study of the antiviral activi- ty [18-20] is still an important phase in the search for new antiviral agents. Thus, the aim of the present study was the screening of the antiviral activity among the range of 4-thiazolidinones with substituents in positions C5 and N3.
Results and DiscussionFor the screening study 4-thiazolidinones con-taining substituents in positions C5 and N3, namely 5-ylidene-4-thiazolidinone-3-carboxylic acids and their derivatives (1-4, 9-29, 32) were selected from the in-home library of the Department of Pharmaceutical, Organic and Bioorganic Chemistry at Danylo Halytsky Lviv National Medical University. Some isosteric com- pounds belonging to 2,4-imidazolidinediones (hydan- toins) (5-8) and 5 alkyl-4-thiazolidinones (30, 31) were involved into the study to estimate the struc- ture-activity relationship. The target compounds were obtained by the methods described earlier: i) rhoda- nine derivatives (1-3, 10, 17-28) – based on rhoda-
nine-3-carboxylic acid with the subsequent modifi-cation of position C5 (under Knoevenagel condensa- tion conditions) and carboxyl groups (under the re-
action of acylation) [7, 21, 22]; ii) compounds 4-9, 
11-16 – based on 2,4-thia(imida)zolidinedione with 
the subsequent modification of position C5 and N3 (under the reaction of alkylation or cyanoethylation) [7]; iii) compounds 29, 30 – based on 2,4-thiazoli- dinedione-5-alkyl (idene)carboxylic acids with the sub- 
sequent modification of the carboxyl group (under the acylation reaction) and position N3 [7, 23] (Fig.).The antiviral activity screening of the compounds synthesized was performed at the National Institute of Allergic and Infectious Diseases of the National In- stitute of Health (Bethesda, MD, USA) within the fra- mework of the international programme – Antimic- robial Acquisition and Coordinating Facility (http:// www.niaid-aacf.org/). The study involved the standard assay protocols regarding coronavirus SARS [24], her- pes viruses (Herpes simplex virus 1 and 2 (HSV-1, HSV-2)), varicella zoster virus (VZV), Epstein-Barr vi- rus (EBV), cytomegalovirus (HCMV) [25], hepatitis C (HCV) [26], and B (HBV) viruses [27], as well as vac-
cinia virus (Vaccinia, Cowpox) and influenza viruses of type A and type B, adeno- and rhinovirus; viruses of biological weapons [28] – Dengue fever virus, yellow fever virus, Takaribe virus, Rift Valley Fever vitus, Ve- nezuelan equine encephalitis virus (VEE), measles vi- 
rus, pig influenza virus (PIV), respiratory syncytial vi- rus (RSV). The results obtained (Tab. 1-4) basically show a low to moderate level of the antiviral activity of the compounds studied.It should be noted that 3-{5-[2-chloro-3-(4-nit- rophenyl)-allylidene]-4-oxo-2-thioxothiazolidine-3-yl}- propanoic acid (1) and 3-{5-[2-chloro-3-(4-nitrophe- nyl)-allylidene]-4-oxo-2-thioxothiazolidine-3-yl}-suc- cinic acid (3) exhibit marked activity levels against Varitsella-Zoster virus (chickenpox) with the selec-tivity index values SI (the ratio of the cytotoxic con-centration to the inhibitory concentration) of 27 and 38, respectively (Table 1). In our opinion, the presen- ce of the “ciminal” (2-chloro-3-(4-nitrophenyl)-pro-penal) moiety in position C5 of the 4-azolidinone core is the most probable determinant. It can be usefull for design of new compounds with the antiviral acti- vity. It is also noted that introduction of the additional carboxyl group (position N3 of compounds 1-3) leads to a drastic decrease of cytotoxicity.A number of compounds, namely 2-7, 16, 17, 25, 
29, 31, is characterized by a significant effect in rela-
tion to influenza viruses (both type A and type B) with SI values within 1.2-3.5. It allows to consider them as powerfull candidates for further optimization (Table 2). In this study it is noted that complications of the C5 sub-stituent (transferring from simple benzylidene frag- ments to substituted derivatives or compounds with 
the phenylpropenylidene fragment) is not an efficient approach to enhance the antiviral activity.Evaluation of the antiviral activity against hepati- tis C and B viruses was conducted for two compounds – 
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Fig. Structures of 4-thia(imida)zolidinones used in the study
Table 1
The antiviral activity of the compounds studied (screening data)
Compound Virus type, (assay) Cell line EC50 EC90 CC50 SI Cytotoxicity (NR, CC50)
1 2 3 4 5 6 7 8
1
HSV-1 (CPE) HFF >12 >12 24 <2
8
HSV-2 (CPE) HFF >12 >12 24 <2
EBV (VCA Elisa) Daudi >0.8 >0.8 >4 <5
HCMV (CPE) HFF >2.4 >2.4 11 <4.6
VZV (CPE) HFF 0.36 1.6 9.6 27
2
HSV-1 (CPE) HFF >0.5 >0.5 1.6 <3.2
1,2
HSV-2 (CPE) HFF >0.5 >0.5 1.6 <3.2
VZV (CPE) HFF >2.4 >2.4 10.1 <4.2
EBV (VCA Elisa) Akata >0.8 >0.8 1 <1.3
3
HSV-1 (CPE) HFF >300 >300 >300 0
229HSV-2 (CPE) HFF >300 >300 >300 0
VZV (CPE) HFF 6.3 24.8 238 38
ACV
HSV-1 (CPE) HFF 1.1
>100
HSV-2 (CPE) HFF 1.0
EBV (VCA Elisa) Daudi 0.2
HCMV (CPE) HFF 0.2
VZV (CPE) HFF 0.2
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24 and 30. These compounds do not possess a sig- nificant antiviral activity. The EC50 values were > 10 
and СС50 – 98 and >100 µg/mL, respectively, (com-pounds 24 and 30) in the hepatitis B virus assay (vi-sual assay, control – 3TC). The percentage inhibition of HCV (replicon RNA) / Huh7 ET was determined for the anti-HCV activity evaluation of the compounds in the concentration of 20 mcM in relation to hepa-titis C. It was 0 and 83% for compounds 24 and 30, 
respectively. The studies of cytotoxicity allowed to determine the selectivity index of action. However, 
SI values were less than 1; and it was not a sufficient argument for further study of these compounds.A moderate antiviral effect of compounds 14, 16, 
21 and 31 has been found as a result of screening of new agents against the severe acute respiratory syndrome better known as SARS. Among the com-pounds mentioned 2-[5-(isatinylidene)-2,4-thiazoli- 
Table 2











EC50 IC50 SI EC50 IC50 SI EC50 IC50 SI EC50 IC50 SI
2 >3 3 0 >2.8 2.8 0 0.32 0.86 2.7 0.34 1.1 3.3
3 >100 >100 0 >100 >100 0 43 >100 >2.3 29 >100 >3.5
4 >100 >100 0 80 >100 >1.3 34 >100 >3 >100 >100 0
5 31 >100 >3.2 91 >100 >1.1 35 >100 >2.8 31 >100 >3.2
6 – – – – – – 38 >100 >2.6 40 >100 >2.5
7 – – – – – – >29 29 0 32 48 1.5
8 – – – – – – >27 27 0 >25 25 0
12 – – – – – – >100 >100 0 >100 >100 0
14 >82 82 0 32 >100 >3.2 >100 >100 0 >93 93 0
16 – – – 32 59 1.9 30 >100 >3.3 29 >100 >3.4
17 – – – – – – >100 >100 0 76 >100 >1.3
19 – – – – – – >30 30 0 >33 33 0
20 >32 32 0 >26 26 0 – – – >32 32 0
21 – – – – – – >27 27 0 31 32 1
24 – – – – – – >29 29 0 32 33 1
25 – – – – – – 45 >100 >2.2 39 61 1.6
27 – – – – – – >9 9 0 >11 11 0
28 – – – – – – >36 36 0 >32 32 0
29 53 >100 >1.9 >100 >100 0 37 >100 >2.7 58 >100 >1.7
30 >100 >100 0 >100 >100 0 >100 >100 >100 >100 0
31 >100 >100 0 36 >100 >2.8 >100 >100 0 >100 >100 0
In parentheses – assay, cell line.
Table continued
1 2 3 4 5 6 7 8
4
Cowpox (CPE) HFF – – – –
Vaccinia (CPE) HFF >300 >300 >300 0
5
Cowpox (CPE) HFF 245 >300 >300 >1.2
Vaccinia (CPE) HFF 228 >300 >300 >1.3
DCV
Cowpox (CPE) HFF
5.2 10.9 >317 317
Vaccinia (CPE) HFF
Hereinafter: ACV – acyclovir; CDV – cidogovir; CPE – inhibition of the cytopathic effect; NR – neutral red assay; 
EC50(90) – concentration of the compound inhibiting virus replication by 50%(90%); CC50 – concentration of the 
compound reducing cells survival by 50% (µg/mL).
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dinedione-3-yl]-N-(4-fluorophenyl)-acetamide (16) is characterized by the highest selectivity index, SI > 3.7 (Table 4).
ConclusionsThe screening of a number of 4-thiazolidinones with substituents in positions C5 and N3 (as the most promising directions of the 4-thiazolidinone struc- ture optimisation) against a wide range of viruses has 
been carried out. It has been found that the compounds under research possess relatively low levels of the an- tiviral activity. However, some active compounds have 
been identified. The compound structures can be con-
sidered as promising basis for further modification in searching for antiviral agents. Among the compounds tested 3-{5-[2-chloro-3-(4-nitrophenyl)-allylidene]- 4-oxo-2-thioxothiazolidinone-3-yl}-propanoic (1) and 3-{5-[2-chloro-3-(4-nirtophenyl)-allylidene]-4-oxo- 
Table 3













EC50 IC50 SI EC50 IC50 SI EC50 IC50 SI EC50 IC50 SI
14 >39 39 0 32 34 1.1 >49 49 0 >48 48 0
16 – – – – – – >46 46 0 >43 43 0
20 – – – >100 3 0 – – – – – –
29 >100 >100 0 >100 >100 0 – – – – – –
31 >40 40 0 >100 >100 0 >100 >100 0 >100 >100 0
Measles virus Chicago 
(NR, CV-1)
Yellow fever virus 
MP-12 (NR, Vero 76)
Tacaribe  
TRVL 11573 (NR, Vero 76)
Rift Valley Fever  
MP-12 (NR, Vero 76)
EC50 IC50 SI EC50 IC50 SI EC50 IC50 SI EC50 IC50 SI
4 – – – >26 26 0 >100 >100 0 >100 100 0
5 – – – 25 26 1 >26 26 0 >71 71 0
13 – – – >58 58 0 >100 >100 0 – – –
14 >63 63 0 – – – – – – – – –
15 – – – – – – 17 77 4.4 >30 30 0
16 >46 46 0 – – – – – – – – –
20 >10 4.8 0 – – – – – – – – –
29 – – – >79 79 0 >51 51 0 – – –
Denge virus 
New Guinea (NR, Vero)
VEE TC-83, 
(NR, Vero)
EC50 IC50 SI EC50 IC50 SI
4 84 >100 >1.2 >100 >100 0
5 >100 >100 0 >100 >100 0
Table 4
The results of anti-SARS screening (Urbani/Vero76, Neutral Red assay)
Compound EC50 IC50 SI Compound EC50 IC50 SI Compound EC50 IC50 SI
1 <10 <10 0 12 >100 >100 0 23 >100 94 0
2 >0.34 0.34 0 14 30 38 1,3 24 <10 <10 0
3 >33 33 0 16 27 >100 >3.7 25 80 15 0
6 >100 >100 0 17 58 90 2 26 >100 >100 0
7 >100 >100 0 18 46 100 2 27 79 100 1
8 >100 >100 0 19 >100 >100 0 29 87 >100 >1.1
9 84 >100 >1 20 69 49 0 30 >100 >100 0
10 20 <10 0 21 <10 19 >2 31 56 >100 >1.8
11 >100 >100 0 22 83 49 0 32 >100 86 0
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a significant activity against Varitsella-Zoster virus 
(VZV) with the selectivity index values – 27 and 38, respectively.
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